Fluctuation and change of serum urate levels and flares in gout: results from the NOR-Gout study

T. Uhlig1,2 · L. F. Karoliussen1 · J. Sexton1 · T. K. Kvien1,2 · E. A. Haavardsholm1,2 · F. Perez-Ruiz3,4,5 · H. B. Hammer1,2

Received: 26 August 2022 / Revised: 11 October 2022 / Accepted: 16 October 2022 / Published online: 1 November 2022
© The Author(s) 2022

Abstract
A gout attack may evolve after a purine-rich diet or alcohol and after starting urate-lowering therapy (ULT). The relationships between fluctuation and change in serum urate (SU) with the occurrence of flares were investigated in this study. In the prospective NOR-Gout study, gout patients with increased SU and a recent flare were treated to target with ULT over 1 year, with follow-up at year 2 with SU and flare as outcomes. SU and flares were assessed at both monthly and 3-monthly intervals until target SU was reached. Fluctuation over periods and changes in SU between two time points were assessed and compared in patients with and without flares. At year 1, 186 patients completed follow-up (88.2%) and 173 (82.0%) at year 2. Mean age (SD) at baseline was 56.4 (13.7) years, disease duration was 7.8 (7.6) years, and 95.3% were men. The first-year SU fluctuation and change were related to flare occurrence during year 1 (both \( p < 0.05 \)). High fluctuation with an absolute sum of all SU changes during the first 9 months was related to flares over 3-month periods (all \( p < 0.05 \)), and high fluctuation during the first 3 months was related to flares in months 3–6 (\( p = 0.04 \)). Monthly and high SU changes or again reaching higher SU levels > 360 µmol/l were not related to flares. Fluctuation and change in SU were related to flare occurrence during the first year of ULT, while changes between visits and reaching SU levels > 360 µmol/L were not related to flares.

Key Points
• Urate-lowering therapy seeks to achieve a treatment target and prevent gout flares, and changes in serum urate are related to gout flares.
• Fluctuation and changes in serum urate were associated with gout flares, suggesting that fluctuation in serum urate is unfavourable during gout treatment.
• During urate-lowering therapy in gout in clinical practice, fluctuation of serum urate, for example, due to lack of adherence, should be observed and avoided.

Keywords Flare · Fluctuation · Gout · Serum urate · Treat to target · Urate-lowering treatment

Introduction
In gout, a prevalent inflammatory joint disease [1–3], hyperuricaemia leads to the formation of monosodium urate (MSU) crystals, followed by flares of inflammation and pain. Urate-lowering therapy (ULT) seeks to reduce serum urate (SU) and prevent gout flares [4, 5]. Flares are frequent after the start of ULT, especially during the first 3–6 months [6, 7], and prophylactic flare treatment is therefore recommended [4].

A gout attack may evolve after a purine-rich diet or alcohol, triggered by a proinflammatory effect of temporary increased serum urate [8]. Flares have also been associated with decreases and fluctuations in urate levels...
in response to pegloticase treatment [9], a finding which supports the hypothesis that not momentary SU levels but rather fluctuations could initiate a flare. Fluctuation of SU is also observed after bariatric surgery with an immediate increase of SU and then a decline after weeks until years [10–12], and increased flares are observed postoperatively [10, 13–15]. Thus, gout flares could be triggered by fluctuation in SU over time, but evidence lacks, especially in routine ULT. We studied whether fluctuation and changes in SU during an intensive ULT approach were related to gout flares over two years.

**Materials and methods**

**Study design and participants**

NOR-Gout (Gout in Norway) is a prospective, observational single-centre study in a hospital-based rheumatology centre where patients satisfying ACR/EULAR classification criteria [16] and with crystal-proven gout were treated with ULT. They were included after a recent flare if SU > 360 μmol/L, ACTRN12618001372279 [17]. The study was approved by the regional ethics committee, included patient representatives in project planning, and was performed in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. All patients provided written informed consent. Diakonhjemmet Hospital sponsored the study.

After a baseline rheumatology outpatient visit at Diakonhjemmet Hospital, ULT was started with allopurinol 100 mg daily with 100 mg increments monthly until treatment target SU < 360 μmol/L (or < 300 μmol/L if clinical tophi were present) was reached, with the maintenance of this dose. Patients switched to febuxostat in case of intolerance or lack of efficacy. Compliance with medication was not specifically tested. Flare prophylaxis was at the discretion of the treating rheumatologist and included colchicine 0.5–1 mg daily for 3–6 months [17] in all but six patients who used low-dose prednisolone.

![STROBE flow diagram of NOR-Gout participants with main examinations](image-url)
Visits, outcome, and covariates

Study visits assessed SU and flare status [7] after 1 month, 2 months, 3 months, 4 months, 6 months, 9 months, and 12 months during year 1 independent of time of flare occurrence, and then after year 1, with additional monthly visits in year 1 if required unless target SU was met.

The primary outcomes were SU and flares after the first year. At every clinical visit, the patient self-reported gout flares since the last visit during a structured interview with a trained study nurse who recorded the flares. If in doubt, the patient and the study nurse discussed whether an experienced episode with pain or swelling was to be defined as a gout flare or not. At all visits, laboratory examinations included SU (µmol/L).

Fluctuation was used as a concept for accumulated positive and negative changes in SU, and was defined as the absolute sum of all observed SU changes between adjacent visits accumulated from baseline to time of observation, i.e. when flare occurrence was studied. SU change was defined as the difference between two visits, between 3-month time points or between years 1 and 2. SU fluctuation and change were compared in patients with and without flares during defined periods.

We also studied the effect of larger SU changes between two visits with thresholds > 30 µmol/L, > 60 µmol/L and > 90 µmol/L for flare occurrence. Finally, we investigated flares among patients who, during the study, had reached the treatment target of < 360 µmol/L. We compared whether a consecutive SU increase to levels > 360 µmol/L and > 400 µmol/L, where an increased risk of MSU crystal formation is anticipated, was associated with flares.

Statistics

Descriptive measures for baseline demographics, SU levels and changes during the study and frequency of flares
were explored with means with differences between groups using independent samples T-test and by the $\chi^2$ test or Fisher's exact. Adjustments for multiple comparisons were not done. $P < 0.05$ was defined as statistically significant. Calculations were performed with IBM SPSS statistics (version 27).

**Results**

**Patient characteristics and visits**

Patient numbers (Fig. 1) at visits were 211 (baseline), 202 (month 1), 193 (month 2), 189 (month 3), 176 (month 4), 167 (month 9), 187 (month 6), 186 (month 12), 173 (24 months) and between 27 and 75 patients met for additional visits. Mean age (SD) at baseline was 56.4(13.7) years, disease duration 7.8(7.6) years, 95.3% were men, 16.6% had clinical tophi, and 73.4% had at least two flares in the year before inclusion.

**SU changes, fluctuations and flares over 2 years**

Mean SU decreased during ULT from 500 (SD 77) to 311 (SD 49) µmol/L in year 1 and 325 (SD 70) µmol/L in year 2. For fluctuation, the mean sum of SU changes from baseline was 196 µmol/L (until 3 months), 274 µmol/L (6 months), 307 µmol/L (9 months), 366 µmol/L (12 months) and 412 µmol/L (until 24 months). A flare during the study was experienced by 80.6% (150/187) during year 1 and 26.0% (45/173) during year 2.

**Association between SU fluctuation and flare**

During year 1, the sum of changes (392 vs. 306 µmol/L, $p = 0.019$) was higher in patients with vs. patients without a flare (Fig. 2).

SU fluctuation during the increasing observation period is related to flare occurrence in 3-month periods. Table 1 shows fluctuation for patients with and without such flares at the end of the observation period and in the subsequent 3-month period. SU fluctuation with sum of changes was higher in patients with flare vs. no flare during the first 3 months ($p = 0.026$), months 3–6 ($p = 0.028$) and months 6–9 ($p = 0.029$). Furthermore, fluctuation until month 3 related to subsequent flare during months 3–6 ($p = 0.038$).

**Association between SU change and flare**

During year 1, SU change was higher in patients with vs. without a flare (193 vs. 160, $p = 0.025$) (Fig. 2).

Monthly or 3-monthly SU changes were not related to flares (Table 2), neither for patients who exceeded threshold changes of 30 to 90 µmol/L.

SU changes over 3-month periods and possible associations to flare occurrence at the next subsequent visit are shown in Table 3, not demonstrating consistent differences between patients with and without flare.

---

**Table 1** Fluctuation of serum urate (mean sum of absolute changes) and flare occurrence in last observed and in a subsequent 3-month period or year 2

| Period (months) | All patients µmol/L (SD) | Flare status | No. SU changes and period for flare (months) |
|----------------|--------------------------|--------------|--------------------------------------------|
| 0–3            | 196 (93) F+ 193 (87) F–  | No. Flare + / F– | 203 (106) 193 (87) *p = 0.026  |
| 0–6            | 274 (140) F+ 186 (82) F–  | 295 (142) 257 (137) *p = 0.028  |
| 0–9            | 307 (166) F+ 291 (137) F–  | 351 (221) 310 (163) *p = 0.029  |
| 0–12           | 366 (223) F+ 409 (251) F–  | 409 (251) 394 (236) *p = 0.08  |
| 0–24           | 413 (247) F+ 449 (259) F–  | 411 (240) 449 (259) *p = 0.19  |

* $P < 0.05$ for comparison Flare + versus Flare –
Table 2  Comparison between patients with and without flares regarding monthly serum urate (SU) change exceeding thresholds

| Month(s) | N     | Mean SU change | p-value | SU change, >30 µmol/L (%) | p-value, flare vs. no flare | SU change, >60 µmol/L (%) | p-value, flare vs. no flare | SU change, >90 µmol/L (%) | p-value, flare vs. no flare |
|----------|-------|----------------|---------|----------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|
| 0–1      | Flare+ | 37             | 192     | 0.16                       | 81.1                      | 0.64                      | 62.2                      | 0.76                      | 48.6                      | 0.41                      |
|          | Flare− | 165            | 82      |                            |                           |                           |                           |                           |                           |                           |
| 1–2      | Flare+ | 25             | 25      | 0.06                       | 48.0                      | 0.30                      | 32.0                      | 0.31                      | 24.0                      | 0.89                      |
|          | Flare− | 166            | 47      |                            |                           |                           |                           |                           |                           |                           |
| 2–3      | Flare+ | 28             | 27      | 0.40                       | 46.4                      | 0.86                      | 28.6                      | 0.94                      | 10.7                      | 0.47                      |
|          | Flare− | 150            | 30      |                            |                           |                           |                           |                           |                           |                           |
| 3–4      | Flare+ | 41             | 3       | 0.28                       | 29.3                      | 0.35                      | 14.6                      | 0.32                      | 25.0                      | 0.93                      |
|          | Flare− | 129            | 11      |                            |                           |                           |                           |                           |                           |                           |
| 4–5      | Flare+ | 14             | 24      | 0.24                       | 50.0                      | 0.90                      | 28.6                      | 0.97                      | 7.1                       | 0.28                      |
|          | Flare− | 52             | 35      |                            |                           |                           |                           |                           |                           |                           |
| 5–6      | Flare+ | 21             | 23      | 0.034                      | 38.1                      | 0.12                      | 23.8                      | 0.22                      | 14.3                      | 0.13                      |
|          | Flare− | 49             | 7       |                            |                           |                           |                           |                           |                           |                           |
| 6–7      | Flare+ | 14             | 42      | 0.08                       | 57.1                      | 0.09                      | 35.7                      | 0.22                      | 21.4                      | 0.14                      |
|          | Flare− | 41             | 13      |                            |                           |                           |                           |                           |                           |                           |
| 7–8      | Flare+ | 6              | 33      | 0.15                       | 50.0                      | 0.51                      | 33.3                      | 0.07                      | 0                         | 0.64                      |
|          | Flare− | 28             | −4      |                            |                           |                           |                           |                           |                           |                           |
| 8–9      | Flare+ | 4              | −18     | 0.30                       | 25.0                      | 0.63                      | 25.0                      | 0.77                      | 0                         | 0.34                      |
|          | Flare− | 32             | 5       |                            |                           |                           |                           |                           |                           |                           |
| 9–10     | Flare+ | 13             | 56      | 0.19                       | 61.5                      | 0.16                      | 38.5                      | 0.60                      | 38.5                      | 0.26                      |
|          | Flare− | 36             | 30      |                            |                           |                           |                           |                           |                           |                           |
| 10–11    | Flare+ | 4              | −38     | 0.14                       | 25.0                      | 0.56                      | 0                         | 0.29                      | 0                         | 0.59                      |
|          | Flare− | 22             | 12      |                            |                           |                           |                           |                           |                           |                           |
| 11–12    | Flare+ | 8              | 6       | 0.46                       | 25.0                      | 0.61                      | 0                         | 0.71                      | 0                         | ND                       |
|          | Flare− | 20             | 7       |                            |                           |                           |                           |                           |                           |                           |
| Period   |       |                |         |                           |                           |                           |                           |                           |                           |                           |
| 0–3      | Flare+ | 59             | 141     | 0.046                      | 88.1                      | 0.07                      | 83.1                      | 0.08                      | 67.8                      | 0.051                     |
|          | Flare− | 139            | 165     |                            |                           |                           |                           |                           |                           |                           |
| 3–6      | Flare+ | 85             | 19      | 0.44                       | 38.8                      | 0.94                      | 28.2                      | 0.57                      | 10.6                      | 0.39                      |
|          | Flare− | 94             | 17      |                            |                           |                           |                           |                           |                           |                           |
| 6–9      | Flare+ | 47             | 10      | 0.10                       | 49.0                      | 0.005                     | 25.5                      | 0.11                      | 25.5                      | 0.13                      |
|          | Flare− | 110            | 26      |                            |                           |                           |                           |                           |                           |                           |
| 9–12     | Flare+ | 59             | 4       | 0.34                       | 32.2                      | 0.18                      | 16.9                      | 0.16                      | 11.9                      | 0.24                      |
|          | Flare− | 104            | 9       |                            |                           |                           |                           |                           |                           |                           |
| 12–24    | Flare+ | 41             | −1      | 0.15                       | 24.4                      | 0.86                      | 11.1                      | 0.91                      | 6.7                       | 0.70                      |
|          | Flare− | 113            | 11      |                            |                           |                           |                           |                           |                           |                           |

*P*-value with independent *t*-test or chi-squared/Fisher exact test for comparisons flare versus no flare

ND, not determinable
Over 2 years, no difference in flare was seen in those patients who, after being at target, again increased SU levels to > 360 mol/L or not, with a flare seen in 86.3% (88/102) among those with increased SU vs. 82.9% (68/82) in those without increased SU, \( p = 0.53 \). Corresponding findings were observed for patients with increased SU to > 400 µmol/L with a flare in 81.0% (34/42) versus flare in 86.5% (122/141) among those without increased SU, \( p = 0.23 \) increase.

Discussion

This study shows that fluctuation and change in SU are related to the occurrence of disease flare. Fluctuation (calculated as the sum of SU changes) was higher in patients with flares during year 1, but this was not observed for year 2. No relation to flares was seen for SU changes between adjacent visits, and not whether patients after initially reaching the treatment target again increased SU towards levels with increased risk of MSU crystal formation.

We found thus that the sum of absolute SU changes over an observation period was a useful indicator of fluctuation, being associated with the occurrence of flare during year 1. High fluctuation up to the 9-month visit was related to flares over 3-month periods, and fluctuation during months 0–3 was related to subsequent flares in months 3–6, thus indicating future flares.

Importantly, our study was performed in a clinical gout setting with intensive ULT, where SU was greatly reduced mainly in the first 3–4 months [17]. At best, a weak association between absolute SU values and flares has previously been reported [17, 18]. Acute gout flares can in the clinic be seen after ingestion of a purine-rich diet and are seen during ULT, possibly as a consequence of remodelling and mechanical disruption of the crystal aggregates with new exposure to monocytes [19], exposing a proinflammatory trigger [8]. In some conditions, SU fluctuation or change has been shown to play a role in increased flares, such as bariatric surgery [10] and pegloticase treatment which may lead to extensive SU fluctuations [9].

We studied a large patient cohort with frequent assessments of both SU and flares which allowed us to study their relationship. We acknowledge limitations in our study due to a one-centre design, lack of a control group excluding causal inferences, and that the study was performed in an intensive ULT setting with predominantly SU reductions. The study design did not allow for capturing rapid daily changes in serum urate due to diet or other factors.

In conclusion, we found that fluctuation in SU during 3-month periods and over the first year after the start with ULT was related to flares and even to subsequent flares in the first months. The sum of changes in SU was a useful way to measure fluctuation. To avoid fluctuations with possible flares, compliance with ULT treatment is important and colchicine prophylaxis over at least 6 months as recommended. Our findings

| Table 3 Serum urate (SU) change over 3-month periods in year 1 and flare occurrence at the next visit |
|----------------|----------------|----------------|----------------|
| Months Flare assessment time Flare status | SU change > 30 µmol/L (%) | p-value, flare vs. no flare | SU change > 60 µmol/L (%) | p-value, flare vs. no flare | SU change > 90 µmol/L (%) | p-value, flare vs. no flare |
| 0–3 | Flare+ | 41 | 170 (89) | 0.13 | 95.1 | 0.63 | 85.4 | 0.33 | 0.86 |
| | Flare− | 129 | 153 (85) | 93.0 | 0.71 | 30.0 | 26.0 | 0.33 | 0.56 |
| 3–6 | Flare+ | 30 | 30 (85) | 0.42 | 36.7 | 0.71 | 0.06 | 0.06 | 0.56 |
| | Flare− | 127 | 22 (71) | 40.2 | 0.43 | 31.3 | 17.2 | 0.28 | 0.67 |
| 6–9 | Flare+ | 47 | 19 (82) | 0.42 | 36.7 | 0.71 | 0.06 | 0.06 | 0.56 |
| | Flare− | 116 | 16 (60) | 31.9 | 0.43 | 31.3 | 17.2 | 0.28 | 0.67 |
| 9–12 | Flare+ | 41 | 11 (63) | 0.15 | 14.6 | 0.043 | 7.3 | 0.043 | 14.2 |
| | Flare− | 113 | 11 (63) | 31.0 | 0.15 | 14.6 | 0.043 | 7.3 | 0.043 | 14.2 |
require confirmation in other longitudinal studies. Findings support existing treatment recommendations with a focus on the gradual increase of ULT to lower SU [4, 5] and reinforce a need for treatment adherence to avoid SU fluctuation.

Acknowledgements We thank research secretary Mona Thorkildsen for organisation and research nurses Gina Stenberg, Anita Reinhard, Heidi Lunse and Ingerid Müller who contributed as trained study nurses in the follow-up of the treat-to-target approach. We also thank patient representatives Espen Reksten and Ole Peter Synestvedt. Contribution from the Dr. Trygve Gythfeldt and wife legacy is appreciated.

Author contribution All authors contributed to the study’s conception and design. Material preparation, data collection and analysis were performed by Till Uhlig, Lars Karoliussen, Joe Sexton, Tore K. Kvien, Espen Haavardsholm, Fernando Perez-Ruiz and Hilde Berner Hammer. The first draft of the manuscript was written by Till Uhlig, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Funding Open access funding provided by University of Oslo (incl Oslo University Hospital).

Data availability The datasets generated during and/or analysed during the current study are available from the corresponding author upon reasonable request.

Declarations

Ethical approval The study was approved by the Norwegian Regional Committee for Medical and Health Research Ethics South East (reference number 2015/990), and the patients gave their written informed consent according to the Declaration of Helsinki.

Conflict of interest The authors declare no competing interests. They have full control of all primary data and that they agree to allow the journal to review their data if requested.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M (2015) Rising burden of gout in the UK but controlling suboptimal management: a nationwide population study. Ann Rheum Dis 74(4):661–667
2. Zhu Y, Pandya BJ, Choi HK (2011) Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum 63(10):3136–3141
3. Dehlin M, Drivelega P, Sigurdardottir V, Svard A, Jacobsson LT (2016) Incidence and prevalence of gout in Western Sweden. Arthritis Res Ther 18:164
4. Richette P, Doherty M, Pascual E, Barkova V, Becce F, Cas- taneda-Sanabria J, Coyfish M, Guillo S, Janssen TL, Janssens H et al (2017) 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 76(1):29–42
5. FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, Gelber AC, Harrold LR, Khanna D, King C et al (2020) 2020 American College of Rheumatology guideline for the management of gout. Arthritis Rheumatol 72(6):879–895
6. Becker MA, Schumacher HR, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N (2005) Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 353(23):2450–2461
7. Uhlig T, Karoliussen LF, Sexton J, Kvien TK, Haavardsholm EA, Perez-Ruiz F, Hammer HB (2022) One- and 2-year flare rates after treat-to-target and tight-control therapy of gout: results from the NOR-Gout study. Arthritis Res Ther 24(1):88
8. Crişan TO, Ciephas MCP, Novakovic B, Erler K, van de Veedonk FL, Stunnenberg HG, Netea MG, Dinarello CA, Joosten LAB (2017) Uric acid priming in human monocytes is driven by the AKT-PRAS40 autophagy pathway. Proc Natl Acad Sci U S A 114(21):5485–5490
9. Mandell BF, Fields TR, Edwards NL, Yeo AE, Lipsky PE (2021) Post-hoc analysis of pegloticase pivotal trials in chronic refractory gout: relationship between fluctuations in plasma urate levels and acute flares. Clin Exp Rheumatol 39(5):1085–1092
10. Yeo C, Kaushal S, Lim B, Syn N, Oo AM, Rao J, Koura A, Yeo D (2019) Impact of bariatric surgery on serum uric acid levels and the incidence of gout-a meta-analysis. Obes Rev 20(12):1759–1770
11. Dalbeth N, Chen P, White M, Gamble GD, Barratt-Boyes C, Gow PJ, Orr-Walker B (2014) Impact of bariatric surgery on serum urate targets in people with morbid obesity and diabetes: a prospective longitudinal study. Ann Rheum Dis 73(5):797–802
12. Li M, Liu Y, Zeng N, Liu J, Bian S, Tian P, Lv H, Zhang M, Zhang P, Zhang Z (2021) Alterations in the serum urate concentrations after bariatric surgery: a short-term prospective observational study. Obes Surg 31(4):1688–1695
13. Friedman JE, Dallal RM, Lord JL (2008) Gouty attacks occur frequently in postoperative gastric bypass patients. Surg Obes Relat Dis 4(1):11–13
14. Antozzi P, Soto F, Arias F, Carroduegos L, Ropos T, Zundel N, Szomstein S, Rosenthal R (2005) Development of acute gouty attack in the morbidly obese population after bariatric surgery. Obes Surg 15(3):405–408
15. Xu C, Wen J, Yang H, You Y, Zhan D, Yu J, Fu L, Zhang T, Liu Y, Yan T (2021) Factors Influencing early serum uric acid fluctuation after bariatric surgery in patients with hyperuricemia. Obes Surg 31(10):4356–4362
16. Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, Brown M, Choi H, Edwards NL, Janssens HJ et al (2015) 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 74(10):1789–1798
17. Uhlig T, Karoliussen LF, Sexton J, Borgen T, Haavardsholm EA, Kvien TK, Hammer HB (2021) 12-month results from the real-life observational treat-to-target and tight-control therapy NOR-Gout study: achievements of the urate target levels and predictors of obtaining this target. RMD Open 7(1):e001628
18. Stamp L, Morillon MB, Taylor WJ, Dalbeth N, Singh JA, Lassere M, Christensen R (2018) Serum urate as surrogate endpoint for flares in people with gout: a systematic review and meta-regres sion analysis. Semin Arthritis Rheum 48(2):293–301
19. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J (2006) Gout-associated uric acid crystals activate the NALP3 inflamma tory pathway. Proc Natl Acad Sci U S A 114(21):5485–5490

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.